Survival and Clinical Outcomes of Patients with Ovarian Cancer Who Were Treated on Phase 1 Clinical Trials

July 24, 2020 3:00 pm

The following article is provided by The Clearity Foundation to support women with ovarian cancer and their families. Learn more about The Clearity Foundation and the services we provide directly to women as they make treatment decisions and navigate emotional impacts of their diagnosis.

platinum resistant

Corr BR, Moroney M, Sheeder J, et al

Given that ovarian cancer patients enrolled on phase 1 trials usually have platinum resistant and heavily pretreated disease, with a poor prognosis, researchers undertook this retrospective single-institution series with 132 patients to evaluate prognostic factors as well as survival among women suffering from recurrent ovarian cancer who were treated on phase 1 clinical trials. They reported an overall response rate of 14.7%. A raised cancer antigen 125 level and albumin < 3.5 g/dL were identified as the independent risk factors predictive of shorter survival. Longer survival was predicted by a BMI > 25 kg/m2. The median overall survival was estimated to be 11.3 months in patients with heavily pretreated ovarian cancer who were treated on phase 1 clinical trials. For cases of heavily pretreated ovarian cancer with a preserved performance status, a reasonable treatment choice is phase 1 clinical trials, when available.

This article was published on MD Linx.

Leave a Reply

Your email address will not be published.

Return to Blog Home Return to Clearity Foundation Home